Clinical trials: Seizures Disorders
Bilateral Hearing Loss
Evaluation of the Benefits of Bilateral Fitting in BAHS Users
The purpose of this study is to evaluate the benefit of bilateral implantation with bone-anchored hearing systems (BAHS), in terms of sound localization abilities, as well as auditory working memory.
- Trial name
- NCT04006132
- Testing
- Fitting of Ponto 3 SuperPower
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Oticon Medical
Epilepsy
Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
The purpose of this study is to examine the safety and effectiveness of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.
- Trial name
- NCT01142193
- Testing
- USL255
- Where
- 69 sites in United States, Argentina and 14 more
- Volunteers
- 249 people
- Sponsor
- Upsher-Smith Laboratories
PCDH19-Related Epilepsy
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in female children and young adults with genetically confirmed PCDH19 gene…
- Trial name
- NCT03865732
- Testing
- Ganaxolone
- Where
- 12 sites in United States, Hungary and 3 more
- Volunteers
- 29 people
- Sponsor
- Marinus Pharmaceuticals
Focal Seizure, Epilepsy
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure…
- Conditions
- Focal Seizure, Epilepsy, Focal Epilepsy
- Trial name
- FOCUS 2 (NCT07594119)
- Testing
- RAP-219
- Where
- 13 sites in United States
- Volunteers
- 312 people
- Sponsor
- Rapport Therapeutics Inc.
Hearing Loss
Clinical Trial Evaluating Outcomes of Self-Fit and Professionally Fit Hearing Aids
Approximately 48 million people in the United States have hearing loss or hearing difficulties in noisy environments. Whisper.ai Inc has previously brought to market a commercial hearing aid system that reduces background noise…
- Trial name
- NCT05527730
- Testing
- Comparison of PRO-FIT or SELF-FIT fitting
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Whisper.ai
Epilepsy
Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)
The purpose of this Phase III study is to assess the long-term safety, tolerability and efficacy of flexibly dosed retigabine Immediate Release (IR) as adjunctive therapy in adult subjects with partial-onset seizures.
- Trial name
- IR (NCT01336621)
- Testing
- Retigabine IR
- Where
- 31 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 98 people
- Sponsor
- GlaxoSmithKline
Epilepsy
A Prospective Diagnostic Belief Updating Study to verIfy the Utility of BioEP in First Seizure Clinics.
The goal of this belief updating study is to assess the utility of BioEP as a complementary support tool in aiding clinical decision making in adults in first seizure clinics.
- Trial name
- PRISTINE (NCT05764252)
- Testing
- BioEP
- Where
- United Kingdom
- Volunteers
- 88 people
- Sponsor
- Neuronostics Ltd
Sleep Deprivation, Epilepsies, Partial
A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures
The purpose of this study is to determine the effects of pregabalin on sleep problems in patients with seizures.
- Trial name
- NCT00643136
- Testing
- Pregabalin
- Where
- 2 sites in Netherlands
- Volunteers
- 17 people
- Sponsor
- Pfizer
Epilepsy
Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
To determine the efficacy and safety of adjunctive open label Zonegran treatment in patients with refractory partial seizures.
- Trial name
- NCT00215592
- Testing
- Zonegran
- Where
- 33 sites in Austria, Denmark and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Eisai Limited
Autosomal Dominant Hypocalcemia
ADH1 and ADH2 Disease Monitoring Study (DMS)
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease…
- Trial name
- CLARIFY (NCT05227287)
- Where
- 27 sites in United States, Australia and 11 more
- Volunteers
- 95 people
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
Hearing Loss, Hearing Impairment
Performance and Effectiveness of a Self-fitting Over-the-counter Hearing Aid
Hearing loss significantly affects quality of life, with sensorineural hearing loss being the most common type among adults. Hearing aids are a proven intervention, yet barriers like access and affordability limit their adoption…
- Trial name
- Lexie (NCT06942325)
- Testing
- OTC self-fitting hearing aid, Prescription hearing aid
- Sponsor
- HearX SA
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
This is an open-label, multicenter study with an Extension Phase to evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to less than [<] 12 years) with…
- Trial name
- NCT02849626
- Testing
- Perampanel
- Where
- 91 sites in United States, Belgium and 10 more
- Volunteers
- 180 people
- Sponsor
- Eisai Inc.
Epilepsy, Partial Seizures
Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
To demonstrate the non-inferiority of Levetiracetam (1000 mg/day) versus Carbamazepine Immediate-Release (400 mg/day) used as monotherapy for at least 6 months in a Chinese population with newly or recently diagnosed Epilepsy who…
- Trial name
- NCT01954121
- Testing
- Levetiracetam, Carbamazepine
- Where
- 28 sites in China
- Volunteers
- 436 people
- Sponsor
- UCB Pharma SA
Seizure Disorders
A Taste and Acceptance Study of FruitiVits in Children Aged 4-8 Years Following a Ketogenic Diet.
Subjects will be asked to substitute their usual vitamin and mineral supplement/s with FruitiVits for seven consecutive days.
- Trial name
- FruitiVits (NCT02229318)
- Testing
- FruitiVits
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Vitaflo International, Ltd
Hepato-splenomegaly, Dysostosis Multiplex
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)
Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of GM1/GM2 from blood
- Conditions
- Hepato-splenomegaly, Dysostosis Multiplex, Seizures, Mental Retardation
- Trial name
- BioGM1/BioGM2 (NCT02298647)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Partial Epilepsy
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy…
- Trial name
- NCT00957047
- Testing
- eslicarbazepine acetate, ESL - Part II
- Where
- Portugal
- Volunteers
- 395 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Lennox Gastaut Syndrome
RNS System LGS Feasibility Study
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or…
- Conditions
- Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures
- Trial name
- NCT05339126
- Testing
- RNS System
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- NeuroPace
Epilepsy
Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures
Zonisamide is already marketed for the treatment of partial seizures in epilepsy. This study is intended to provide evidence that zonisamide is safe and effective in the treatment of primary generalised tonic-clonic seizures.
- Trial name
- NCT00692003
- Testing
- Zonisamide
- Where
- 73 sites in Australia, Croatia and 11 more
- Volunteers
- 21 people
- Sponsor
- Eisai Limited
Epilepsy, Focal Seizures
A Study of GWP42006 in People With Focal Seizures - Part B
To investigate the potential antiepileptic effects of GWP42006 as add-on therapy in subjects with inadequately controlled focal seizures.
- Trial name
- NCT02365610
- Testing
- GWP42006
- Where
- 26 sites in Czechia, Hungary and 4 more
- Volunteers
- 162 people
- Sponsor
- Jazz Pharmaceuticals
Epilepsy
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
- Trial name
- NCT01091662
- Testing
- Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg
- Where
- 62 sites in United States, Bulgaria and 3 more
- Volunteers
- 172 people
- Sponsor
- Sumitomo Pharma America, Inc.